Researchers from the Perelman School of Medicine at the University of Pennsylvania have made a discovery about muscular dystrophy disorders that suggest new possibilities for treatment.
In an effort to explore ways to improve observational skills among medical students, researchers from Perelman School of Medicine at the University of Pennsylvania and Children’s Hospital of Philadelphia, in collaboration with educators at the Philadelphia Museum of Art, turned to the field of visual arts to examine if training in art observation, description, and interpretation could be applied to medical training.
Patients with the most common type of liver cancer who are taking the chemotherapy drug sorafenib can begin their treatment with a lower dose than is currently considered standard, and it will not affect how long they live when compared to patients who start on the full dose.
The Patient Protection and Affordable Care Act (ACA) of 2010, also known as Obamacare, aimed to achieve parity in coverage between mental health care and other forms of health care. A new study from researchers at the Perelman School of Medicine at the University of Pennsylvania suggests that ACA plans may still fall short of that goal.
An experimental imaging tool that uses a targeted fluorescent dye successfully lit up the benign brain tumors of patients during removal surgery, allowing surgeons to identify tumor tissue
A large analysis of genetic data has looked into what causes type-2 diabetes, and second clarified how type-2 diabetes and coronary heart disease – the two diseases that are the leading cause of global morbidity and mortality — are linked.
In a landmark decision for the field of cancer immunotherapy, the U.S. Food and Drug Administration today approved a personalized cellular therapy developed by the University of Pennsylvania and Children’s Hospital of Philadelphia for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
The more the surface area of the body is covered by psoriasis, the greater the risk of death for the patient suffering from the condition, according to a new analysis by researchers in the Perelman School of Medicine at the University of Pennsylvania.
Ian A. Blair, PhD, an internationally recognized expert on applying mass spectrometry, which measures the characteristics of individual molecules, to biomedical problems and drug development, has won the 2017 Founders’ Award from the Division of Chemical Toxicology of the American Chemical Society. Blair, who has held scientific appointments on five continents, is the A.N. Richards Professor of Pharmacology and director of the Center for Cancer Pharmacology at the Perelman School of Medicine at the University of Pennsylvania.
For Patients and the General Public: